Agenus to trim its staff numbers and assets
Agenus is looking to go all in on its lead solid tumor combo, but it will effectively halt work on its other assets and cut …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
